Clinical trial NCT06158100: Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Official title: A Phase 1 Study of Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Keywords: Hematopoietic Cell Transplant (HCT)
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: AbbVie
First posted: 2023-12-06
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Phase 1 dose escalation/de-escalation and dose expansion design.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see the effects of an investigational combination treatment of venetoclax, azacitidine, and donor lymphocyte infusion (DLI) in patients with high-risk AML receiving allogeneic hematopoietic cell transplantation, and to assess if the combination treatment is well tolerated and prevents disease relapse after transplant.


Eligibility criteria: Inclusion Criteria:

1. Male and female patients between the ages of 18-75.
2. Patients with a histologic diagnosis of AML in morphological remission (\<5% bone marrow (BM) blasts) prior to allogeneic hematopoietic cell transplantation and very high-risk for relapse defined as: (i) Presence of measurable residual disease (MRD) by multicolor flow cytometry (MFC) prior to transplant and receiving a reduced intensity conditioning (RIC) or nonmyeloablative (NMA) regimen (ii) Presence of MRD by MFC at day +30 post-transplant (iii) All patients with monosomal karyotype (MK) and those with 17p/tumor protein p53 (TP53) mutated disease irrespective of MRD status and intensity of conditioning regimen.
3. Adequate hematopoietic recovery after HCT, defined as:

   * Absolute neutrophil count (ANC) \>= 1 x 10\^9/L without daily use of myeloid growth factors
   * Platelet count \>= 50 x 10\^9/L without platelet transfusion within 1 week
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
5. Serum creatinine =\< 1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min
6. Serum bilirubin =\< 1.5 x upper limit of normal (ULN)
7. Aspartate transaminase (AST) or alanine transaminase (ALT) =\< 2.5 x ULN
8. Alkaline phosphatase =\< 2.5 x UL
9. Negative serum or urine pregnancy test for women with reproductive potential.
10. A negative donor-specific antibody (DSA) assay (i.e., Micro-Flow Imaging (MFI) \<m3000) for recipients of any mismatched graft (including haploidentical) HCT.

Exclusion Criteria:

1. Active disease (\>5% blasts or any evidence of extra-medullary disease) at the time of transplantation or at day +30
2. Active acute graft-versus-host disease (aGVHD) requiring systemic IST or history of aGVHD grade III or higher.
3. Active chronic GVHD requiring systemic immunosuppressive therapy (IST).
4. Active uncontrolled systemic fungal, bacterial, or viral infection
5. Known active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
6. Significant active cardiac disease within the previous 6 months, including: New York Heart Association (NYHA) class III or IV congestive heart failure. Unstable angina, angina requiring surgical or medical intervention, and/or myocardial infarction.
7. History of any other malignancy within 2 years prior to study entry, except for: adequately treated in situ carcinoma of the cervix or carcinoma in situ of breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; myelodysplastic syndrome.

Primary outcomes:
measure: Recommended Phase 2 Dose (RP2D)
timeFrame: Up to 13 months
measure: Number of Participants Experiencing Treatment-Related Toxicity
timeFrame: Up to 13 months
Secondary outcomes:
measure: Recurrence-Free Survival (RFS)
timeFrame: Up to 24 months
measure: Overall Survival (OS)
timeFrame: Up to 24 months
measure: Proportion of Participants with Treatment-Related Mortality (TRM)
timeFrame: 180 days
measure: Number of Participants with acute GVHD After Allogeneic Hematopoietic Cell Transplant (HCT)
timeFrame: Up to 180 days
measure: Number of Participants with chronic GVHD After Allogeneic Hematopoietic Cell Transplant (HCT)
timeFrame: 1 year
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Antonio M Jimenez Jimenez, MD
role: PRINCIPAL_INVESTIGATOR
References: